Immutep Secured Third United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Portfolio Pulse from Charles Gross
Immutep Limited has been granted a third US patent (number 11,684,654) for Eftilagimod Alpha in combination with a PD-1 pathway inhibitor. This follows the grant of the parent patent and first divisional patent announced in December 2020 and March 2021.
June 27, 2023 | 8:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immutep's third US patent for Eftilagimod Alpha in combination with a PD-1 pathway inhibitor may boost investor confidence and potentially increase the stock price.
The grant of a third US patent for Immutep's Eftilagimod Alpha strengthens the company's intellectual property portfolio and may lead to increased investor confidence. This could result in a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100